Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-GLOBAL platform trial for stroke
NCT06352632Phase 3Recruiting
- Sponsor
- The George Institute for Global Health
- Start
- Sep 2024
- Primary completion
- Sep 2034
- Modality
- Nucleic Acid-Directed Small Molecules, Peptides, Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of tenecteplase, NoNO-42, deferoxamine, colchicine, tissue-plasminogen activator in stroke, sponsored by The George Institute for Global Health. Started Sep 2024; status: recruiting.
02
Drugs
tenecteplaseNoNO-42deferoxaminecolchicinetissue-plasminogen activator
03
Conditions
stroke
Beyond the preview
Go deeper on NCT06352632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352632.